

Docket No.: PU60031

ASSIGNMENT

WHEREAS We, Jeffrey K. KERNS, of King of Prussia, PA USA, a citizen of United States of America; Qi JIN of King of Prussia, PA USA, a citizen of China; Hong NIE of King of Prussia, PA USA, a citizen of China; Zehong WAN of King of Prussia, PA USA, a citizen of China; Chongjie ZHU of King of Prussia, PA USA, a citizen of China; have made an invention entitled:

QUINOLINE DERIVATIVES AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS

for which on an even date we executed an application for Letters Patent of the United States under 35 U.S.C. §111(a), executed an application for Letters Patents of the United States under 35 U.S.C. §371, or filed a Provisional application under 35 U.S.C. §111(b):

NOW, THEREFORE, in return for valuable consideration paid to us by SmithKline Beecham Corporation, a corporation organized under the laws of the Commonwealth of Pennsylvania and having its principal place of business at One Franklin Plaza, Philadelphia, Pennsylvania 19101, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, we do hereby assign unto the said SmithKline Beecham Corporation, its successors and assigns, the entire right, title and interest in and to the said invention, executed under 35 U.S.C. §111(a), 35 U.S.C. §371, or filed under 35 U.S.C. §111(b) application, and from which priority may be claimed from one or more 35 U.S.C. §111(b) applications, or any division, continuation and continuation-in-part of said application, and all Letters Patent of the United States and all foreign countries to be obtained therefor;


We further assign to the said SmithKline Beecham Corporation the right, optionally in its own name or in the names of its related companies, to apply for, obtain and maintain in all countries foreign to the United States, patent and/or Utility Model applications for said invention, including the full right to claim for any such application the benefits of any priority rights based on said executed United States application;

And we agree to execute further instruments (including provisional, divisional, continuation, continuation-in-part or reissue applications or other instruments) proper to effectuate the premises, this agreement to be binding upon our heirs, executors and administrators;



And we request the Commissioner of Patents and Trademarks of the United States, and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue Letters Patent in accordance herewith.


Jeffrey K. KERNS


Date: 29 January 2004


Qi JIN

Date: 29 January 2004


Hong NIE

Zehong WAN

Date: 29 January 2004


Chongjie ZHU

Date: 29 January 2004